Ixiaro: Japanese encephalitis vaccine approved for paediatric use

Children aged 2 months and older can now receive the Japanese encephalitis vaccine, Ixiaro.

Japanese encephalitis is found in most countries in Asia and also in some remote parts of northeast Australia | SCIENCE PHOTO LIBRARY
Japanese encephalitis is found in most countries in Asia and also in some remote parts of northeast Australia | SCIENCE PHOTO LIBRARY

Dosage regimen

The dose for children aged between 2 months and 3 years is 0.25ml and for children aged 3 to 18 years is 0.5ml. The lower dose is administered using the existing 0.5ml prefilled syringe but healthcare professionals must discard the excess volume before injection, as directed in the product literature. For both age groups, the vaccine should be given as two doses 28 days apart. There are no data available on booster doses in the paediatric population.

Give by intramuscular injection

The vaccine should be injected intramuscularly into the deltoid muscle; however, the anterolateral aspect of the thigh may be used in infants. The subcutaneous route may be used in patients with bleeding disorders, although there are no clinical efficacy data to support administration by this route.

Efficacy supported by two key studies

Evidence supporting this licence extension comes from two key randomised, open-label studies investigating the immunogenicity and safety in children aged between 2 months and 18 years. The first study was conducted in the Philippines, a country where JEV is endemic, and the second is an ongoing, uncontrolled trial in non-endemic countries (the US, Europe and Australia) in subjects with planned travel to an endemic area.

In both studies, seroconversion rates, defined as JEV neutralising antibody titre ≥1:10, were at least 85% at month 7 following vaccination. The safety profile was comparable to that of Havrix or Prevenar.

View Ixiaro drug record

Further information: Novartis Vaccines

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Early emollient use does not prevent eczema in children, studies show

Early emollient use does not prevent eczema in children, studies show

Daily application of emollients in infancy is not effective...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...